XML 32 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
    
The Company recognized no revenue and $705 during the year ended December 31, 2023 and 2022, respectively.

Revenue recognized during the year ended December 31, 2022 consists of amounts received from the Company’s license and commercialization agreement with Eurofarma Laboratórios S.A. Revenue recognized during the year ended December 31, 2022 was from Latin America. The analysis of revenue by geography has been identified on the basis of the geographical location of each collaboration partner.

The following table summarizes the deferred revenue relating to Eurofarma Laboratórios S.A. and deferred other income relating to BARDA (as defined in Note 9):
2023
2022
Beginning deferred revenue and other income, January 1
$— $7,939 
Additions— 1,397 
Amount of deferred revenue and other income recognized in the statement of operations— (8,790)
Foreign currency adjustment— (546)
Ending deferred revenue and other income, December 31
$— $— 

Refer to Note 9 below for further details regarding other income recognized under the BARDA contract.